NEO241220C6000
- 0.00
- 0.000.00%
NeoGenomics Newsroom
NeoGenomics To Present Four Studies At AMP 2024 Showcasing CtDNA And NGS Advancements For Cancer Diagnostics And Personalized Treatment
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of CtDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Felicia Williams Joins NeoGenomics Board of Directors
Express News | Felicia Williams Joins Neogenomics Board of Directors
Earnings Scheduled For November 14, 2024
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $18 to $21
A Quick Look at Today's Ratings for NeoGenomics(NEO.US), With a Forecast Between $18 to $20
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), NeoGenomics (NEO) and Ultragenyx Pharmaceutical (RARE)
NeoGenomics: Balancing Growth in NGS With ADx Challenges Amid Strategic Progress
NeoGenomics | 10-Q: Q3 2024 Earnings Report
NeoGenomics, Inc. (NEO) Q3 2024 Earnings Call Transcript Summary
NeoGenomics' Strong Financial Performance and Growth Potential Earns Buy Rating
NeoGenomics: Q3 Earnings Snapshot
NeoGenomics | 8-K: NeoGenomics Reports Third Quarter 2024 Results
NeoGenomics Non-GAAP EPS of $0.05 Beats by $0.04, Revenue of $167.82M Beats by $0.79M
Express News | Neogenomics Inc Q3 Shr View $0.01 -- LSEG IBES Data
NeoGenomics Cash and Cash Equivalents and Marketable Securities Totaled $388 M at Qtr End >NEO
Earnings Flash (NEO) NEOGENOMICS Reports Q3 EPS $0.05